Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $167.00

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) had its price target upped by equities researchers at JPMorgan Chase & Co. from $165.00 to $167.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an "overweight" rating on the biotechnology company's stock. JPMorgan Chase & Co.'s target price points to a potential upside of 30.93% from the company's previous close.

Other equities research analysts also recently issued research reports about the stock. Oppenheimer lowered their price objective on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating for the company in a research report on Friday, November 15th. Stifel Nicolaus boosted their price objective on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a "buy" rating in a research report on Friday, November 15th. TD Cowen lowered their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating for the company in a research report on Friday, November 15th. UBS Group started coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a "buy" rating and a $196.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $170.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $191.57.

Ascendis Pharma A/S Stock Down 1.4 %

Shares of ASND traded down $1.82 during midday trading on Wednesday, hitting $127.55. The company had a trading volume of 191,953 shares, compared to its average volume of 459,655. The company's 50 day moving average price is $133.46 and its 200 day moving average price is $133.07. The stock has a market cap of $7.74 billion, a price-to-earnings ratio of -15.79 and a beta of 0.65. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $161.00.

Institutional Trading of Ascendis Pharma A/S

Institutional investors have recently made changes to their positions in the stock. Wilmington Savings Fund Society FSB acquired a new stake in shares of Ascendis Pharma A/S in the 3rd quarter worth approximately $30,000. Blue Trust Inc. lifted its stake in shares of Ascendis Pharma A/S by 540.5% in the 4th quarter. Blue Trust Inc. now owns 506 shares of the biotechnology company's stock worth $76,000 after acquiring an additional 427 shares during the period. GAMMA Investing LLC lifted its stake in shares of Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock worth $80,000 after acquiring an additional 214 shares during the period. Signaturefd LLC lifted its stake in Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company's stock valued at $102,000 after purchasing an additional 80 shares during the last quarter. Finally, Pursue Wealth Partners LLC acquired a new stake in Ascendis Pharma A/S during the third quarter valued at approximately $217,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.